SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819
This study is recruiting at 10 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Sumitomo Pharma America, Inc.
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Cedars Sinai Medical Center · Los Angeles, CA
Colorado · 1
- Sarah Cannon Research Institute at HealthOne · Denver, CO
Florida · 1
- Advent Health · Celebration, FL
Illinois · 2
- Northwestern Medicine Cancer Center · Chicago, IL
- The University of Chicago · Chicago, IL
Ohio · 1
- Ohio State University · Columbus, OH
Tennessee · 2
- SCRI Oncology Partners · Nashville, TN
- Vanderbilt-Ingram Cancer Center · Nashville, TN
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Washington · 1
- University of Washington · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.